IRIS
FRANCINI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.154
EU - Europa 10.799
AS - Asia 6.952
SA - Sud America 1.046
AF - Africa 241
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 15
Totale 34.239
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.970
CN - Cina 2.627
GB - Regno Unito 2.433
SG - Singapore 2.120
RU - Federazione Russa 2.046
IE - Irlanda 1.540
UA - Ucraina 1.152
BR - Brasile 883
SE - Svezia 863
FR - Francia 806
DE - Germania 721
IT - Italia 602
VN - Vietnam 576
HK - Hong Kong 564
KR - Corea 362
FI - Finlandia 354
IN - India 161
ZA - Sudafrica 119
BD - Bangladesh 112
CA - Canada 101
AR - Argentina 57
TR - Turchia 55
ES - Italia 54
IQ - Iraq 52
MX - Messico 48
NL - Olanda 45
PL - Polonia 39
PK - Pakistan 36
SA - Arabia Saudita 33
ID - Indonesia 32
JP - Giappone 32
NG - Nigeria 31
AU - Australia 27
MA - Marocco 25
BE - Belgio 24
EC - Ecuador 24
CI - Costa d'Avorio 23
CL - Cile 22
UZ - Uzbekistan 20
VE - Venezuela 19
AT - Austria 18
PH - Filippine 17
CZ - Repubblica Ceca 16
IR - Iran 16
AE - Emirati Arabi Uniti 15
EU - Europa 15
MY - Malesia 15
NP - Nepal 13
CO - Colombia 11
KE - Kenya 11
DK - Danimarca 10
JO - Giordania 10
LT - Lituania 10
JM - Giamaica 9
TH - Thailandia 9
BG - Bulgaria 8
PE - Perù 8
PY - Paraguay 8
TW - Taiwan 8
UY - Uruguay 8
AZ - Azerbaigian 7
LB - Libano 7
OM - Oman 7
RO - Romania 7
TN - Tunisia 7
EG - Egitto 6
KZ - Kazakistan 6
AL - Albania 5
CR - Costa Rica 5
IL - Israele 5
NZ - Nuova Zelanda 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
HU - Ungheria 4
MD - Moldavia 4
PS - Palestinian Territory 4
QA - Qatar 4
AM - Armenia 3
BO - Bolivia 3
CH - Svizzera 3
EE - Estonia 3
GR - Grecia 3
GY - Guiana 3
HR - Croazia 3
KW - Kuwait 3
MM - Myanmar 3
PA - Panama 3
PT - Portogallo 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
CD - Congo 2
CG - Congo 2
CY - Cipro 2
Totale 34.204
Salva come PNG Salva come JPEG
Città #
Southend 2.112
Dallas 1.823
Dublin 1.523
Fairfield 1.506
Singapore 1.199
Ashburn 1.087
Chandler 979
Jacksonville 935
Woodbridge 772
Wilmington 640
Seattle 620
Santa Clara 612
Houston 581
Beijing 572
Moscow 564
Hong Kong 538
Cambridge 477
San Jose 466
Hefei 434
Seoul 359
Nanjing 345
Ann Arbor 343
Princeton 311
New York 301
The Dalles 288
Los Angeles 191
Ho Chi Minh City 174
Lauterbourg 171
Siena 153
San Mateo 148
Hanoi 138
Boardman 134
Helsinki 119
Munich 112
Nanchang 112
Johannesburg 103
Buffalo 96
San Diego 91
São Paulo 65
Shanghai 62
Council Bluffs 61
Dong Ket 61
Changsha 50
Milan 50
Hebei 49
Shenyang 48
Tianjin 48
Redondo Beach 47
Kunming 45
Norwalk 45
Turku 43
Bengaluru 40
Frankfurt am Main 40
Orem 39
Toronto 39
Columbus 38
London 38
Jiaxing 36
San Francisco 36
Málaga 32
Warsaw 32
Rio de Janeiro 31
Abuja 29
Guangzhou 28
Tokyo 28
Lancaster 27
Brooklyn 26
Montreal 26
Zhengzhou 26
Amsterdam 25
Hangzhou 25
Ningbo 25
Brussels 24
Chicago 23
Abidjan 22
Belo Horizonte 22
Chennai 22
Haiphong 22
Rome 21
Baghdad 20
Da Nang 20
Düsseldorf 20
Jinan 20
Tashkent 20
Nuremberg 19
Washington 19
Atlanta 18
Fremont 18
Boston 17
Denver 17
Philadelphia 17
Dhaka 16
Manchester 16
Menlo Park 16
Stockholm 16
Auburn Hills 15
Porto Alegre 15
Biên Hòa 14
Campinas 14
Phoenix 14
Totale 22.986
Salva come PNG Salva come JPEG
Nome #
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. 351
Survival following early-stage colon cancer: An ACCENT-based comparison of patients versus a matched international general population 332
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma 326
A62Effectiveness and resulting surgical behavior after neoadjuvant chemotherapy in locally advanced breast cancer: our experience 313
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 311
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma 307
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. 305
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid 289
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 289
70 Tumor associated hypercalcemia 283
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation 281
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 265
Peptidi epitopici immunogenici del CEA da utilizzare nella chemio-immunoterapia del carcinoma del colon-retto e della mammella. 263
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients 261
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer 260
Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases 256
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 256
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. 255
A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate camcer metastates, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2 251
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine 250
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience 250
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 244
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. 243
Dendritic cell-cediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro 243
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 236
Bioactivity of GM-CSF and IL-2 in cancer patients 234
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey 234
Folinic Acid and 5-Fluorouracil as adjuvant chemotherapy in colon cancer 230
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer 228
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 227
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients 225
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mytomicin C 224
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity 224
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer 221
A Poly-epitopic peptide vaccine against the thymidylate synthase (TS). A synergistic therapeutic combination with fluoropyrimidine-based-chemotherapy 219
A five-day treatment of tumor-induced hypercalcemia by intravenous amino-hexane (AHBP) or aminobutane (ABBP) bisphosphonate 218
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia 215
Quality of life in advanced colorectal cancer 213
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient 213
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study 212
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 211
GEMCITABINE (dFdC), 5-FLUROURACIL (5FU), AND FOLINIC ACID (FA) IN THE TREATMENT OF PATIENTS WITH GASTRO-ENTERIC CARCINOMAS: A CLINICAL AND PHARMACOLOGICAL STUDY. 210
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer 210
Doxetacel and epirubicin compared with doxetacel and prednisone in advanced castrate-resistant prostate cancer: a randomized phase II study 209
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 208
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) 208
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 207
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. 206
Virosoma dell'influenza immunoricostituito (IRIV) contenente il gene per CD40L come immunoprotettore tumorale CEA-specifico e usi immunogenici di esso. 205
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study: TILs for ADJ-untreated stage II colon cancer 205
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. 204
Hepatoid gastric carcinoma. A case report 204
Analgesic activity and side effects of different calcitonins in man 203
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens 202
Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. 200
Chemo-immunotherapy of colo-rectal cancer: Drug induced antigen specific cell-mediated immune response in vitro and in cancer patients 199
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate 197
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies 197
Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases 194
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer 193
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials 193
Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. 193
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? 191
Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine 190
Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 189
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 188
Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 187
Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man 187
Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy 186
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane 186
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials 183
Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer 183
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. 180
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. 180
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. 179
Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation 178
Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care 178
Palliative chemotherapy for relief of subocclusive symptoms 177
Squamocellular gallbladder carcinoma associated with multiple small pigment stones long term after total gastrectomy 177
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy 174
Analgesic effect of salmon calcitonin nasal pray on bone pain 174
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 174
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 173
Is endocrine hyperactivity a favourable prognostic factor in the chemotherapic treatment of bronchogenic carcinoma? 173
Seasonal variation in urinary excretion of cyclic AMP in healthy people 171
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. 170
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel 169
Osteoblastic metastases: Metabolic and morphologic aspects 169
Hypercalcemia and urinary excretion of cyclic AMP in bronchogenic carcinoma 168
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study 168
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen 167
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma 167
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials 167
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study 167
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. 165
Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes 163
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab 163
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer 163
THYMIDYLATE SYNTHASE RELATED POLYEPITOPE PEPTIDE CANCER THERAPEUTICS 162
Weekly epirubicin in patients with hormone-resistant prostate cancer 162
Totale 21.363
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.076
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.076
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021256 0 0 0 0 0 0 0 0 0 0 0 256
2021/20222.295 174 300 193 179 95 59 96 91 122 246 230 510
2022/20233.467 225 201 427 519 346 758 56 318 386 59 113 59
2023/20242.217 111 58 165 69 61 725 741 39 2 47 44 155
2024/20254.369 107 274 297 252 516 202 74 216 375 164 517 1.375
2025/202610.309 861 1.731 1.338 1.025 1.910 428 1.243 326 389 593 288 177
Totale 34.386